logo

For the Inventor, By the Inventor

Gilbertsville, PA, United States of America

Jasbir Singh

This inventor holds 15 USPTO granted patents. Top assignees: Cephalon, Inc., Vertex Pharmaceuticals, Inc., Nycomed Imaging as. Active years: 1996-2007.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jasbir Singh. Retrieved from https://idiyas.com/inventor/jasbir-singh-49xiulz3

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 15

% Patents Active = 86.7

Average Co-Inventor Count = 4.0

ph-index = 6

Forward Citations = 164(Granted Patents)


Location History:

  • Wayne, PA (US) (1999)
  • Gilbertsville, PA (US) (1996 - 2007)

Company Filing History:

goldMedal7 out of 248 
 
Cephalon, Inc.
 patents
silverMedal3 out of 1,167 
 
Vertex Pharmaceuticals, Inc.
 patents
bronzeMedal2 out of 162 
 
Nycomed Imaging as
 patents
4. 1 out of 46 
 
Amersham Health as
 patents
5. 1 out of 1,544 
 
Sanofi
 patents
6. 1 out of 16 
 
Sanofi Winthrop Inc.
 patents

Years Active: 1996-2007

Loading Chart...
15 patents (USPTO):Explore Patents
1. 7288650 - Cyclic substituted fused pyrrolocarbazoles and isoindolones (2007-10-30),
2. 7074793 - Cyclic substituted fused pyrrolocarbazoles and isoindolones (2006-07-11),
3. 6841567 - Cyclic substituted fused pyrrolocarbazoles and isoindolones (2005-01-11),
4. 6831075 - Heterocyclic substituted pyrazolones (2004-12-14),
5. 6576614 - Peptide analogs as irreversible interleukin-1&bgr; protease inhibitors (2003-06-10),
6. 6455525 - Heterocyclic substituted pyrazolones (2002-09-24),
7. 6423296 - Constrast media (2002-07-23),
8. 6359130 - Bridged indenopyrrolocarbazoles (2002-03-19),
9. 6280706 - Chelating agents (2001-08-28),
10. 6127401 - Bridged indenopyrrolocarbazoles (2000-10-03),
11. 6004529 - Chelating agents (1999-12-21),
12. 5985838 - Peptide analogs as irreversible interleukin-1.beta. protease inhibitors (1999-11-16),
13. 5843905 - Peptidic phosphinyloxymethyl ketones as interleukin-1.beta.-converting (1998-12-01),
14. 5677283 - .alpha.-heteroaryloxymethyl ketones as interleukin - 1 .beta. converting (1997-10-14),
15. 5585357 - Heteroaryloxymethyl ketones as interleukin-1.beta.converting enzyme (1996-12-17),

Title: The Innovative Journey of Jasbir Singh

Introduction

Jasbir Singh is a notable inventor based in Gilbertsville, PA (US). He has made significant contributions to the field of chemistry, holding a total of 15 patents. His work primarily focuses on the development of novel compounds that have potential applications in various industries.

Latest Patents

Among his latest inventions are cyclic substituted fused pyrrolocarbazoles and isoindolones. The present invention is directed to cyclic substituted fused pyrrolocarbazoles and isoindolones. The invention also encompasses methods for making and using these cyclic substituted fused pyrrolocarbazoles and isoindolones. This innovative approach showcases his commitment to advancing chemical research and applications.

Career Highlights

Throughout his career, Jasbir Singh has worked with prominent companies such as Cephalon, Inc. and Vertex Pharmaceuticals, Inc. His experience in these organizations has allowed him to refine his skills and contribute to groundbreaking research in the pharmaceutical sector.

Collaborations

Some of his notable coworkers include Rabindranath Tripathy and Robert L. Hudkins. Their collaborative efforts have likely played a role in the successful development of various projects and patents.

Conclusion

Jasbir Singh's contributions to the field of chemistry and his impressive portfolio of patents highlight his innovative spirit and dedication to advancing scientific knowledge. His work continues to inspire future generations of inventors and researchers.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…